References

1. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989; 12: 553-64.

2. Luft D, Schmülling R, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia 1978; 14:75-8.

3. Colwell J. Is it time to introduce metformin in the U.S.? Diabetes Care 1993; 16:653-5.

4. Johansen K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999; 22:33-7.

5. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-9.

6. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49:721-49.

7. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102:99-110.

8. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15:755-72.

9. Klip A, Leiter L. Cellular mechanism of action of metformin. Diabetes Care 1990; 13:696-704.

10. Bailey C. Metformin revisited: its actions and indications for use. Diabet Med 1988; 5:315-20.

11. Hermann L. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990; 13:37-41.

12. Bailey C, Nattrass M. Treatment—metformin. Baillieres Clin Endocrinol Metab 1988; 2:455-76.

13. U.K. Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.

14. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-9.

15. Hermann LS, Kjellstrom T, Nilsson-Ehle P. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabet Metab 1991; 17:174-9.

16. Matthaei S, Stumvoll M, Kellerer M, Hairing HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21:585-618.

17. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-74.

18. Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006; 574(Pt 1):41-53.

19. Carling D. LKB1: a sweet side to Peutz-Jeghers syndrome? Trends Mol Med 2006; 12:144-7.

20. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-6.

21. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:707-13.

22. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. Diabetes Care 1992; 15: 318-68.

23. Nosadini R, Avogaro A, Trevisian R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10:62-7.

24. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550-4.

25. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81:4059-67.

26. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non-insulin-dependent diabetes mellitus. Diabet Metab 1986; 12:346-50.

27. Jackson R, Hawa M, Jaspan J, et al. Mechanism of metformin action in noninsulin-dependent diabetes. Diabetes 1987; 36:632-40.

28. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73:1294-301.

29. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42:1217-22.

30. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabet Rev 1998; 6:89-131.

31. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49:2063-9.

32. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43:920-8.

33. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 1989; 120:257-65.

34. Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabet Metab 1991; 17:180-4.

35. McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP. Metformin increases insulin sensitivity and basal glucose clearance in type 2 diabetes mellitus. Aust N Z J Med 1991; 21: 714-9.

36. Wu M, Johnston P, Sheu W, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13:1-8.

37. DeFronzo RA. The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes 1988; 37:667-87.

38. Widen E, Eriksson J, Groop L. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41:354-8.

39. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13:415-31.

40. Wing RR, Koeske R, Epstein LH, Norwalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147:1749-53.

41. Morel Y, Golay A, Pernegert T, et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabet Med 1999; 16:650-5.

42. Scheen AJ, Letiexhe MR, Lefebvre PJ. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med 1995; 12: 985-9.

43. Diamanti Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269-74.

44. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, doubleblind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85:139-46.

45. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphen-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876-80.

46. Hermann L. Metformin: a review of its pharmacologic properties and therapeutic use. Diabet Metab 1975; 5:233-45.

47. McLelland J. Recovery from metformin overdose. Diabet Med 1985; 2:410-1.

48. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes. Diabetologia 1999; 42:406-12.

49. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44:107-12.

50. Robinson AC, Johnston DG, Burke J, Elkeles RS, Robinson S. The effect of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabet Care 1998; 21:701-5.

51. Gin H, Messerchmitt C, Brottier E, Aubertin J. Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism 1985; 34:923-5.

52. Pagano G, Tagliaferro V, Carta Q, et al. Metformin reduces insulin requirements in type 1 (insulin-dependent) diabetes. Diabetologia 1983; 24:351-4.

53. Gin H, Slama G, Weissbrodt P, et al. Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 1982; 23: 34-6.

54. Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabet Care 1998; 21:1301-5.

55. Cigolini M, Bosello O, Zancanaro C, Orlandi PG, Fezzi O, Smith U. Influence of metformin on metabolic effects of insulin in human adipose tissue in vitro. Diabet Metab 1984; 10:311-5.

56. Puhakainen I, Yki-Jarvinen H. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production. Diabetes 1993; 42: 1694-9.

57. Saloranta C, Taskinen M, Widen E, Harkonen M, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993; 42: 1559-66.

58. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol 1990; 39:1831-4.

59. Penicaud L, Hitier Y, Ferre P, Girard J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989; 262: 881-5.

60. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994; 112:671-5.

61. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24:49-57.

62. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-9.

63. Bellomo R, McGrath B, Boyce N. In vivo catecholamine extraction during continuous hemofiltration in inotrope-dependent patients. ASAIO Trans 1991; 37:M324-5.

64. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6:47-53.

65. Leslie P, Jung Rt, Isles TE, Baty J. Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulfonylurea therapy. Clin Sci 1987; 73:41-5.

66. Stumvoll M, Meyer C, Mitrakou A, Nadkarni V, Gerich J. Renal glucose production and utilization. New aspects in humans. Diabetologia 1997; 40:749-57.

67. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102:619-24.

68. Matthaei S, Hamann A, Klein HH, et al. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 1991; 40: 850-7.

69. Matthaei S, Reibold JP, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993; 133: 304-11.

70. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-9.

71. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49:721-49.

72. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102:99-110.

73. Johansen K. Efficacy of metformin in the treatment of NIDDM. Diabetes Care 1999; 22:33-7.

74. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.

75. Lalor BC, Bhatnagar D, Winocour PH, et al. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med 1990; 7:242-5.

76. Teupe B, Bergis K. Prospective randomized two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabet Metab 1991; 17:213-7.

77. Dornan T, Heller S, Peck G, Tattersall R. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991; 14:342-4.

78. Nagi D, Yudkin J. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16:621-9.

79. Tessari P, Biolo G, Bruttomesso D, et al. Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes. J Clin Endocrinol Metab 1994; 79:1553-60.

80. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19:64-6.

81. Rains S, Wilson G, Richmond W, Elkeles R. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 1988; 5:653-8.

82. Collier A, Watson HH, Patrick AW, Ludlam CA, Clarke BF. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabet Metab 1989; 15:420-5.

83. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 1990; 7:510-4.

84. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabet Metab 1991; 17:209-12.

85. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res 1992; 19:69-76.

86. Hermann LS, Kjellstrom T, Schersten B, Lindgarde F, Bitzen P, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994; 17:1100-9.

87. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabet Metab 1994; 20:394-400.

88. Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 1999; 22:38-44.

89. Reaven G, Johnston P, Hollenbeck C, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992; 74:1020-6.

90. Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16:1387-90.

91. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229:181-7.

92. Schneider J, Erren T, Zofel P, Kaffarnik H. Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus. Atherosclerosis 1990; 82:97-103.

93. Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994; 235:335-41.

94. Landin K, Tengborn L, Smith U. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost 1994; 71:783-7.

95. Pentikainen PJ, Voutilainen E, Aro A, Uusitupa M, Penttila I, Vapaatalo H. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med 1990; 22:307-12.

96. Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991; 8: 361-5.

97. Gin H, Freyburger G, Boisseau M, Aubertin J. Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 1989; 6:61-7.

98. Saenz A, Fernandez-Esteban J, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 20:CD002966.

99. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabet Metab 1994; 20: 15-9.

100. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diabet Metab 1991; 17:218-23.

101. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005; 21:2029-35.

102. Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2006; 66:85-109.

103. Hanuschak LN. Metformin useful in combination with exogenous insulin [letter]. Diabetes Care 1996; 19:671-2.

104. Aviles-Santa A, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin treated type 2 diabetes. Ann Int Med 1999; 131:182-8.

105. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Int Med 1999; 130:389-96.

106. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998; 338:265-6.

107. Oates NS, Shah RR, Idle JR, Smith RL. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34:827-34.

108. Kreisberg R, Pennington L, Boshell B. Lactate turnover and gluconeogenesis in obesity: effect of phenformin. Diabetes 1970; 19:64-9.

109. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18:779-84.

110. Nathan DM. Some answers, more questions, from UKPDS. Lancet 1999; 352:832-3.

111. Nathan DM, Buse JB, Davidson Mb, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-72.

112. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.

113. Garber A, Duncan T, Goodman A, Mills D, Rohlf J. Efficacy of metformin in type-II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 102:491-7.

114. Buse J Combining insulin and oral agents. Am J Med 2000; 108 (Suppl. 1):23-32.

0 0

Post a comment